These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22103243)

  • 1. Cyclobutane derivatives as novel nonpeptidic small molecule agonists of glucagon-like peptide-1 receptor.
    Liu Q; Li N; Yuan Y; Lu H; Wu X; Zhou C; He M; Su H; Zhang M; Wang J; Wang B; Wang Y; Ma D; Ye Y; Weiss HC; Gesing ER; Liao J; Wang MW
    J Med Chem; 2012 Jan; 55(1):250-67. PubMed ID: 22103243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities.
    He M; Guan N; Gao WW; Liu Q; Wu XY; Ma DW; Zhong DF; Ge GB; Li C; Chen XY; Yang L; Liao JY; Wang MW
    Acta Pharmacol Sin; 2012 Feb; 33(2):148-54. PubMed ID: 22301855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
    Han J; Sun L; Chu Y; Li Z; Huang D; Zhu X; Qian H; Huang W
    J Med Chem; 2013 Dec; 56(24):9955-68. PubMed ID: 24308627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
    Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists.
    Zhang YJ; Shen LL; Cheon HG; Xu YN; Jeong JH
    Arch Pharm Res; 2014 May; 37(5):588-99. PubMed ID: 24178744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.
    Xiao Q; Giguere J; Parisien M; Jeng W; St-Pierre SA; Brubaker PL; Wheeler MB
    Biochemistry; 2001 Mar; 40(9):2860-9. PubMed ID: 11258897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
    Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M
    J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
    Miranda LP; Winters KA; Gegg CV; Patel A; Aral J; Long J; Zhang J; Diamond S; Guido M; Stanislaus S; Ma M; Li H; Rose MJ; Poppe L; Véniant MM
    J Med Chem; 2008 May; 51(9):2758-65. PubMed ID: 18412318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.
    Evers A; Bossart M; Pfeiffer-Marek S; Elvert R; Schreuder H; Kurz M; Stengelin S; Lorenz M; Herling A; Konkar A; Lukasczyk U; Pfenninger A; Lorenz K; Haack T; Kadereit D; Wagner M
    J Med Chem; 2018 Jul; 61(13):5580-5593. PubMed ID: 29879354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truxillic acid derivatives act as peroxisome proliferator-activated receptor gamma activators.
    Steri R; Rupp M; Proschak E; Schroeter T; Zettl H; Hansen K; Schwarz O; Müller-Kuhrt L; Müller KR; Schneider G; Schubert-Zsilavecz M
    Bioorg Med Chem Lett; 2010 May; 20(9):2920-3. PubMed ID: 20347594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
    Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
    Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Mol Cell Endocrinol; 2019 Jan; 480():54-64. PubMed ID: 30312651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets.
    Sloop KW; Willard FS; Brenner MB; Ficorilli J; Valasek K; Showalter AD; Farb TB; Cao JX; Cox AL; Michael MD; Gutierrez Sanfeliciano SM; Tebbe MJ; Coghlan MJ
    Diabetes; 2010 Dec; 59(12):3099-107. PubMed ID: 20823098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
    Chen D; Liao J; Li N; Zhou C; Liu Q; Wang G; Zhang R; Zhang S; Lin L; Chen K; Xie X; Nan F; Young AA; Wang MW
    Proc Natl Acad Sci U S A; 2007 Jan; 104(3):943-8. PubMed ID: 17213311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
    Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
    Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.
    Mapelli C; Natarajan SI; Meyer JP; Bastos MM; Bernatowicz MS; Lee VG; Pluscec J; Riexinger DJ; Sieber-McMaster ES; Constantine KL; Smith-Monroy CA; Golla R; Ma Z; Longhi DA; Shi D; Xin L; Taylor JR; Koplowitz B; Chi CL; Khanna A; Robinson GW; Seethala R; Antal-Zimanyi IA; Stoffel RH; Han S; Whaley JM; Huang CS; Krupinski J; Ewing WR
    J Med Chem; 2009 Dec; 52(23):7788-99. PubMed ID: 19702274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
    Méndez M; Matter H; Defossa E; Kurz M; Lebreton S; Li Z; Lohmann M; Löhn M; Mors H; Podeschwa M; Rackelmann N; Riedel J; Safar P; Thorpe DS; Schäfer M; Weitz D; Breitschopf K
    J Med Chem; 2020 Mar; 63(5):2292-2307. PubMed ID: 31596080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species-specific differences in agonistic activity of ago-allosteric modulators toward glucagon-like peptide 2 receptor.
    Yamazaki K; Takase K; Watanabe M; Kagaya T; Terauchi H; Iida D; Fukumoto H; Suzuki S; Arai T; Aoki M; Seiki T; Tsukahara K; Nagakawa J
    Biomed Res; 2012 Dec; 33(6):337-44. PubMed ID: 23268957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.